Kairos Pharma Enters Into Binding Terms To Acquire CL-273 From Celyn Therapeutics For Undisclosed Sum; Transaction Is Expected To Be Value‑Accretive

The next‑generation, AI‑designed pan‑EGFR inhibitor for EGFR‑mutant lung cancer significantly expands the Company's oncology pipeline Targeting a $16.2 Billion Market Opportunity

Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it has entered into binding terms to acquire CL-273 from Celyn Therapeutics, Inc., a company backed by OrbiMed and Torrey Pines Investment.

CL-273 is an investigational, reversible, wild-type-sparing pan‑EGFR small‑molecule inhibitor discovered using a proprietary AI-driven drug discovery platform backed by OrbiMed and other leading healthcare investors. This unique drug targets the resistant mutations that develop when using EGFR tyrosine kinase inhibitors, thereby reversing resistance. Specifically engineered for EGFR‑mutant type of lung cancer (NSCLC), the EGFR‑mutated lung cancer treatment market is estimated at $16.2 billion in 2026 (Future Market Insights). EGFR mutations are present in approximately 10–15% of NSCLC cases in Western populations and up to 50% in Asian populations (CoherentMI), creating a substantial addressable patient population worldwide.

Celyn Therapeutics brings deep domain expertise in small‑molecule oncology drug development. Kairos Pharma believes that OrbiMed's support of Celyn underscores the quality of CL‑273's discovery and this transaction is expected to align the Company with OrbiMed's longstanding track record in building category‑defining oncology companies. By acquiring CL‑273, Kairos aims to accelerate the development of a next‑generation, AI‑designed EGFR inhibitor for patients with EGFR‑mutant NSCLC worldwide.